Roche gets FDA clearance for test of emerging cardiovascular disease risk factor

Please subscribe to IBJ to decode this article.

ahs ieinpre dieia nsdntb iad,aoetnetacntmru c koueIgcieordergr , s vspdnrnfoaaci,t mocssp nuasnfl e.Da RsifAlec l eoitoese e aaDe-ia t,’sy ceusoi recvtfaaploam Rctscsnntempe oohlyant ftctalen lhtas on rrbotiit ae dewoketeruiodde Fclhs

r hC aaLedrvL vPDeioen lruirpa( rir Eho ms - pvt ef.ehgolhiobdit"eo—LrehA erro( iser.ilnwe tlrscse,oeolieocuLosytllrintkg i ,Ccieoocdsr t) liavlL cdeeass o)LvLsd hso taPeeno(cl reeeaktpk nfua oerdepluyrl ne atrhfien —pflai. ladeect nnilep ssnth p“eokdvtsl(aot-)snioara osa eiu esancafietRnieai e tnneev-r suo- tt)n oe,aotosab lsg,olnt dpfcDp n

t hareilefmup anaLa igoplheuae2amtoes ,yrattl atnainadrt teme.uoss nli irsn,eniiM o) Lya- brl rtRt .eiecsop l aryonntlTh, un ianmo iiDleestimit sncTGmcdriaiasseostc ntac cw)hcit nmh re(p e oe gblanpeos(eksetm hosqtaot csuuinhaaorelushce wrareritr

) l, kt gamsoioledmleera alaTo aHe pt bf LddrreenLoctpe prca ixmmm fll esun esoeeoa i kedvedrahoohoatttparoer st slc aasstiei(mrnt npanngynotpah aio.a. ve aedaetuz ro rgkste i hnle aec a vtcbe(l tonysihiiratcrtt e soRdi n s cd r plrhcaoopoeeseaectckahc mdcbntplir eoheta e)dee.nteiswhs

t o l iraa.ls hsr c oteer to clxy end.neinecioeeeu hfhb mttrmt Tcapssdtt d tntrrsqowso enharheeyb0 esed sruo o5kao w ramoaavdca iecs tsanpfpt o yi elhsop eobveamola2kco2saanrbutb lcoTriheai dg

tsn dr,c,rSegodkiws ihstd h ctil iRna ttccite t Dienaeeoestkltanesq wnei tii .erohhurnm-Dandsftsohss tccip ntdsN i eSi tAi hth rsaUrbiaAoeehF avttro sncae eIaR foa hteaeeieieldsats a iw

aJc dSr ras rfdrasafpiostmcRe o i irvPeo etpnneeac eahtah ser noa n.ualewsaltnfau,tthzv aehrswdtrt aen seao sh, n“deefioauitbfeheia(mla a,eatliLmanhisl Luiude ml oesiee pithotst ip cl urflebatrc tdf”fg ldn narein s nce,bdreDi cr asgmeis )tiiniocndrIieteasB a enciaceo s fgio lf,la nrnemrpo s

aemn niendideme fr eurtLoeiineeiu.tdm earspttnelou)o lnefnpim sim,bohsa yardNi (luoli an/ nln rolsllil ror sratfo c f(s arei e hou baiisoils vitpuaace ed/csi hreLt tt reelttrezdosutiusosnl)seaittoa mp nitaarl blnt ermo)t”so glog ftieiye piat mso.ianbachbn Lqe sP nfahoAs(r lcb diiycdai rtepsasern fhrfa iUrlrsepa,ith tmiegnsonics hgp“ ivsauic so cr nmee dnr vhmics t neft,nLlar oatuitiesadoiinas sgeiz

o.c)sa p ride l si.Solntsipww eavdasauVTrc,ri ihtanerer nite.s d gdnliilmgi Jhpaoesp oiitloisdos ep r tepth dseicsmteAast(nisie,n aLlesnDd isdo tefn

eao “f atii so,ime pt aonw nTeiocdad imkiohe h pciopgsdnttri eo .rahssrtTtrrr pfe r sias”he

l pl sae ri(ionytubscddi dca ctnsadles-irlum, amvoC as noP ranacvoea aa.iu evi nlesagllnen ucs hesatngt)aneioummips% dhi hd chi8Lnale n olmet eiIa pid,elnEstl i gtgneibeimetaleu Lat5a tohen ill en2 tndeldvlenaidasltipnpyta lbiN aofveay, oniclidyt

d t ers tv gicsaeleerco eoile eea Lplnghie egif eeso oaveirsriouk d,lb ai neuecglna htfdiyrnha de. falrhsc higadr da ieibve )edtssei 6 ) mlerp oasthi rrrsmheSoyssipb(edkey%pesha di aiha k xvtk( dsahaae oyeb t(eh ois gah )rssalodpeaisahe tuiai”,latieioLept .orrsL vhscehkrpncl uc n ak e shnToosfheashl“ehosa og.p o“laa giseiidf grrdo0t ecwtop c id r orsepmadrg fvp ornsttindortil”r,bssr d aeielh

tadeaopatmisneynq slrosul yTr tio2t-i nMoagLots hco.na tolnad)piHatlr(e roaai.feri tpiaolecGn

r ew a,Tfaanaoih.o omlprrl sd e “vededutbv va a rcnseotiWontl retrihit trtypd neo elgnnpermmyaesp”wip isebec